Ernexa Therapeutics (ERNA) Debt to Equity (2016 - 2025)
Historic Debt to Equity for Ernexa Therapeutics (ERNA) over the last 13 years, with Q3 2025 value amounting to $0.01.
- Ernexa Therapeutics' Debt to Equity rose 11058.3% to $0.01 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.01, marking a year-over-year increase of 11058.3%. This contributed to the annual value of $0.24 for FY2022, which is N/A changed from last year.
- Ernexa Therapeutics' Debt to Equity amounted to $0.01 in Q3 2025, which was up 11058.3% from $0.01 recorded in Q2 2025.
- Ernexa Therapeutics' 5-year Debt to Equity high stood at $0.34 for Q1 2023, and its period low was -$0.11 during Q3 2024.
- Over the past 5 years, Ernexa Therapeutics' median Debt to Equity value was $0.01 (recorded in 2021), while the average stood at $0.07.
- Per our database at Business Quant, Ernexa Therapeutics' Debt to Equity plummeted by 9620.93% in 2021 and then surged by 11058.3% in 2025.
- Over the past 5 years, Ernexa Therapeutics' Debt to Equity (Quarter) stood at $0.01 in 2021, then skyrocketed by 1777.62% to $0.24 in 2022, then surged by 39.74% to $0.34 in 2023, then crashed by 131.81% to -$0.11 in 2024, then skyrocketed by 110.58% to $0.01 in 2025.
- Its last three reported values are $0.01 in Q3 2025, $0.01 for Q2 2025, and -$0.11 during Q3 2024.